Indutrade

Indutrade reports a 23% rise in net profit to SEK 784m for the second quarter, on revenue up 11% to SEK 8.99bn. Order intake grew 14% to a record SEK 9.41bn and the EBITA margin improved to 14.7%. Organic growth benefited from higher demand in medical technology, pharmaceuticals and energy, while five acquisitions in the quarter and nine YTD (together ~SEK 1.5bn annual sales) strengthen growth prospects; management nonetheless points to geopolitical and macroeconomic uncertainties. » More on de.investing.com

Indutrade reports a strong operating cash flow of SEK 1,595m for Q4 2025, an adjusted EBITA margin of 14.9% (previous year 14.3%) and a quarterly profit of SEK 626m. Order intake rose 2% in the quarter to SEK 8,196m, while net sales were stable on a currency-adjusted basis. For the full year the company reports net sales of SEK 32.2bn, an EBITA margin of 13.8% and free operating cash flow of SEK 3.5bn; the board proposes a dividend increase to SEK 3.10 per share. Indutrade completed 13 acquisitions in 2025 with around SEK 1.3bn in annual sales and sees a gradual demand picture with continued market uncertainty. » More on de.investing.com

Indutrade recorded a net sales decline of 4% to SEK 8.1bn in Q2 2025 while order intake was unchanged. EBITA fell 11% to SEK 1,115m and the EBITA margin dropped to 13.7%, and operating cash flow decreased by 29%. Acquisitions contributed +3% to growth; four add‑ons with combined annual sales of SEK 425m were completed year‑to‑date and management reports a strong pipeline. Net debt improved to 1.5x EBITDA, but the company remains cautious due to ongoing market uncertainty and has announced a Capital Markets Day on 4 November. » More on de.investing.com